Last Updated On 3/21/2024 8:39:23 AM
This is a disclosure report of the user financial relationships with for-profit health care companies.
All relationships are considered compensated unless otherwise noted. Relationships are self-held unless otherwise noted.
| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| No Relationships to Disclose |
|
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Novartis |
| Recipient: Your Institution |
| Company: Roche/Genentech |
| Recipient: Your Institution |
| Company: Mirati Therapeutics |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: Takeda |
| Recipient: Your Institution |
| Company: Lilly |
| Recipient: Your Institution |
| Company: Pfizer |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases |
| Recipient: Your Institution |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| Company: Bayer |
| Recipient: You |
| Company: Merck |
| Recipient: You |
|
| Other Relationship |
| Company: Pfizer |
| Recipient: You |
| Company: Roche/Genentech |
| Recipient: You |
| Company: Takeda |
| Recipient: You |
| Company: Mirati Therapeutics |
| Recipient: You |
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| No Relationships to Disclose |
|
|